Loading…
OmniAb, Inc. is projected to rise to $2.70 by 2027, a +17% move from its current price of $2.31. OABI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $2.23 | $2.31 | $2.39 | +0.05% |
| Jul 13 | $2.20 | $2.31 | $2.42 | +0.09% |
| Jul 14 | $2.17 | $2.31 | $2.45 | +0.14% |
| Jul 15 | $2.15 | $2.31 | $2.48 | +0.18% |
| Jul 16 | $2.14 | $2.31 | $2.50 | +0.23% |
| Jul 17 | $2.12 | $2.31 | $2.52 | +0.27% |
| Jul 18 | $2.11 | $2.31 | $2.54 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.11 | $2.31 | $2.54 | +0.32% |
| Week 2 | $2.03 | $2.32 | $2.65 | +0.64% |
| Week 3 | $1.98 | $2.33 | $2.73 | +0.96% |
| Week 4 | $1.94 | $2.33 | $2.81 | +1.28% |
| Week 5 | $1.90 | $2.34 | $2.88 | +1.60% |
| Week 6 | $1.87 | $2.35 | $2.95 | +1.92% |
| Week 7 | $1.84 | $2.36 | $3.02 | +2.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
OmniAb, Inc. is a biotechnology company that licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.
Its technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. The OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics.
The company offers animal-based technologies including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb was founded in 2012 and is headquartered in Emeryville, California. It has an agreement with mAbsolve Ltd.
for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform.
OmniAb, Inc. trades under the symbol OABI and operates in the Healthcare category. The current price is $2.32 and the market cap is $336.34M, with a rank of 3408.
The long-range price outlook is bullish, with a year-by-year forecast showing gradual upside across 2026 through 2050. The forecast starts at an average of $2.32 in 2026 and progresses to $22.75 by 2050, underscored by sizable projected ROIs in later years.
A major floor 41.0% below — a decisive break under it would weaken the trend.
The nearest floor, 12.4% below — buyers have tended to step in here.
The nearest ceiling, 18.0% above — a clean break opens room to run.
A major ceiling 32.0% above — clearing it would confirm fresh momentum.
Key OABI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OABI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.31 | Sell | $2.31 | Sell |
| MA 10 | $2.39 | Sell | $2.34 | Sell |
| MA 20 | $2.32 | Sell | $2.34 | Sell |
| MA 50 | $2.22 | Buy | $2.22 | Buy |
| MA 100 | $1.94 | Buy | $2.06 | Buy |
| MA 200 | $1.85 | Buy | $2.02 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.19 | Neutral |
| Stoch RSI (14) | 16.91 | Buy |
| CCI (20) | -21.17 | Neutral |
| Williams %R (14) | -84.85 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -1.72 | Sell |
| Bollinger %B (20,2) | 0.44 | Neutral |
| Stochastic %K (14) | 15.15 | Buy |
| TRIX (15) | 0.25 | Buy |
| Awesome (5,34) | -0.10 | Sell |
| Ultimate (7,14,28) | 33.17 | Neutral |
| Momentum (10) | -0.22 | Sell |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 2.24 | Buy |
| ADX (14) | 14.97 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is bullish.
RSI (14) is 50, with the 50-day simple moving average at $2.17 and the 200-day simple moving average at $1.84, suggesting price momentum has room to rise toward near-term averages.
Support sits at $2.02 and resistance at $2.72, framing a near-term range with the thirty-day price band shown as $1.81 to $2.98. Annualized volatility is elevated at 70%, underscoring a high-m variability backdrop.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.36 | $2.31 | $3.00 | 0% | Neutral | |
| $2.09 | $2.70 | $3.72 | +17% | Neutral | |
| $2.58 | $3.46 | $4.99 | +50% | Bullish | |
| $3.17 | $4.37 | $6.54 | +90% | Bullish | |
| $3.22 | $4.58 | $7.05 | +99% | Bullish | |
| $3.22 | $4.69 | $7.42 | +104% | Bullish | |
| $3.34 | $4.99 | $8.06 | +116% | Bullish | |
| $3.53 | $5.39 | $8.90 | +134% | Bullish | |
| $4.27 | $6.65 | $11.19 | +189% | Bullish | |
| $4.80 | $7.64 | $13.09 | +232% | Bullish | |
| $6.07 | $10.63 | $19.58 | +361% | Bullish | |
| $10.54 | $21.87 | $44.78 | +849% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.36 | $2.31 | $2.79 | +0.00% |
| August 2026 | $1.94 | $2.31 | $2.83 | +0.08% |
| September 2026 | $2.00 | $2.40 | $2.99 | +4.14% |
| October 2026 | $2.06 | $2.49 | $3.14 | +3.68% |
| November 2026 | $1.98 | $2.41 | $3.07 | -3.22% |
| December 2026 | $1.91 | $2.34 | $3.00 | -2.98% |
Click any year to see its month-by-month OABI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, OABI is projected to trade between $1.36 and $3.00, averaging $2.31 — a potential gain of 0% from today's $2.31. Price action looks broadly range-bound.
OmniAb, Inc.'s 2027 outlook centres on $2.70, within a $2.09 to $3.72 range. That is up +17% on the projected 2026 average. That marks a +17% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, OABI could reach as high as $4.99, with a base case around $3.46 and support toward $2.58 — roughly +50% from $2.31. Momentum favours further upside here.
Expect OABI to range from $3.17 to $6.54 through 2029. The $4.37 average target implies a +90% move from current prices. That is up +26% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The OABI price prediction for 2030 points to an average of $4.58 (low $3.22, high $7.05) — a potential gain of +99% on today's $2.31. Momentum favours further upside here.
In 2031, OABI is projected to trade between $3.22 and $7.42, averaging $4.69 — a potential gain of +104% from today's $2.31. That is up +3% on the projected 2030 average. Buyers look set to stay in control over this stretch.
OmniAb, Inc.'s 2032 outlook centres on $4.99, within a $3.34 to $8.06 range. That is up +6% on the projected 2031 average. That marks a +116% change versus current levels. Momentum favours further upside here.
By 2033, OABI could reach as high as $8.90, with a base case around $5.39 and support toward $3.53 — roughly +134% from $2.31. Buyers look set to stay in control over this stretch.
Expect OABI to range from $4.27 to $11.19 through 2034. The $6.65 average target implies a +189% move from current prices. That is up +23% on the projected 2033 average. Momentum favours further upside here.
The OABI price prediction for 2035 points to an average of $7.64 (low $4.80, high $13.09) — a potential gain of +232% on today's $2.31. Buyers look set to stay in control over this stretch.
In 2040, OABI is projected to trade between $6.07 and $19.58, averaging $10.63 — a potential gain of +361% from today's $2.31. That is up +39% on the projected 2035 average. Momentum favours further upside here.
OmniAb, Inc.'s 2050 outlook centres on $21.87, within a $10.54 to $44.78 range. That is up +106% on the projected 2040 average. That marks a +849% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in OABI today (≈ 433.839479 OABI) could be worth
$9,488.34
+$8,488.34 (+849%) by 2050 · US Dollar
Based on the average projected OABI price of $21.87 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OABIwould be worth at today's price.
$1,000 invested in OABI on Jul 10, 2025 (≈ 485.436907 OABI) would be worth
$1,118.93
+$118.93 (+11.9%) today · 1.12× · US Dollar
Based on a OABI entry price of $2.06 vs. today's $2.31.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.42 | $952.48 | -4.8% |
| 1 month ago | $2.38 | $968.49 | -3.2% |
| 3 months ago | $1.47 | $1,568.03 | +56.8% |
| 6 months ago | $1.91 | $1,206.81 | +20.7% |
| 1 year ago | $2.06 | $1,118.93 | +11.9% |
| All time (4.8y) ago | $9.76 | $236.17 | -76.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OABI forecast.
Our base-case forecast reaches $4.60 around 2031.
Implied market cap at $4.60: $666.87M
The multi-year forecast lays out a clear upside trajectory. The average price is projected to rise from $2.32 in 2026 to $4.71 in 2030, $11.00 in 2040, and $22.75 in 2050. Corresponding ROI figures show 0% in 2026, 17.9% in 2027, 52.1% in 2028, 94.7% in 2029, 102.9% in 2030, 105.6% in 2031, 120.4% in 2032, 137.9% in 2033, 194.8% in 2034, 243% in 2035, 374.2% in 2040, and 880.4% in 2050.
The forecast shifts from neutral in 2026–2027 to bullish from 2028 onward, with the strongest upside represented in the 2040 and 2050 milestones. These figures provide a view of potential long-run appreciation, but they are estimates and not guarantees. Risks and uncertainties should be considered, and investment decisions should be made accordingly.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $4.71 with a low of $3.25 and a high of $7.38; ROI is 102.9% and sentiment is BULLISH.
The year-by-year forecast indicates neutral sentiment in 2026 and 2027, then bullish momentum from 2028 onward, with the average price rising to $22.75 by 2050 and ROIs reaching 880.4%. These are estimates, not guarantees.
Yes. The forecast lists a 2033 maximum of $9.32, with higher potential in later years (e.g., 2034 max $11.78; 2035 max $13.96; 2040 max $20.84; 2050 max $48.10).
$1.81 to $2.98.
Current price is $2.32, market cap is $336.34M, and rank is 3408.
OmniAb, Inc. Community Discussion
0Share your OmniAb, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.